NCT01585649View on ClinicalTrials.gov

PK/PD of XM22 in Children With Ewing Family of Tumors or Rhabdomyosarcoma

PHASE1CompletedINTERVENTIONAL

Enrollment

21

Participants

Timeline

Start Date

July 31, 2012

Primary Completion Date

June 30, 2014

Study Completion Date

April 30, 2015

Conditions

Ewing Family of Tumors, Rhabdomyosarcoma

Interventions

DRUG

Lipegfilgrastim

Lipegfilgrastim 100ug/kg

Trial Locations (18)

Unknown

Teva Investigational Site 0103, Plovdiv

Teva Investigational Site 0101, Sofia

Teva Investigational Site 0102, Varna

Teva Investigational Site 0201, Prague

Teva Investigational Site 0301, Budapest

Teva Investigational Site 0401, Lublin

Teva Investigational Site 0501, Chelyabinsk

Teva Investigational Site 0507, Krasnodar

Teva Investigational Site 0505, Moscow

Teva Investigational Site 0506, Moscow

Teva Investigational Site 0508, Moscow

Teva Investigational Site 0502, Saint Petersburg

Teva Investigational Site 0504, Yekaterinburg

Teva Investigational Site 0701, Dnipropetrovsk

Teva Investigational Site 0705, Donetsk

Teva Investigational Site 0702, Kharkiv

Teva Investigational Site 0704, Kyiv

Teva Investigational Site 0703, Lviv

All Listed Sponsors

lead

Merckle GmbH

INDUSTRY

NCT01585649 - PK/PD of XM22 in Children With Ewing Family of Tumors or Rhabdomyosarcoma | Biotech Hunter | Biotech Hunter